Lipocine earnings release, August 4, 2026

Lipocine Inc. (LPCN) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Lipocine

Announces Financial Results for the Second Quarter Ended June 30, 2026

SALT

LAKE CITY, August 4, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the second quarter ended June 30, 2026 and provided a corporate update.

Recent

Developments and Corporate Update

LPCN

1154 (BRLIZIO™) for Postpartum Depression (PPD)

LPCN

2201 for Major Depressive Disorder

LPCN

2203 for Essential Tremor

TLANDO

Second

Quarter Ended June 30, 2026 Financial Results

As of June 30, 2026, Lipocine had $23.3 million of unrestricted cash, cash equivalents, and marketable investment securities, compared to

$14.9 million at December 31, 2025.

Lipocine reported a net loss of $2.6 million, or ($0.32) per diluted share, for the quarter ended June 30, 2026, compared to a net loss of $2.2 million, or ($0.41) per diluted share, for the quarter ended June 30, 2025.

Royalty revenue from TLANDO sales were $190,000 during the three months ended June 30, 2026, compared to $123,000 during the three months ended

June 30, 2025. In addition, license revenue of $500,000 was recognized in the three months ended June 30, 2025 and there was no license revenue in the comparable period of 2026.

Research and development expenses were $2.0 million and $2.1 million, respectively, for the quarters ended June 30, 2026 and 2025.

General and administrative expenses were $1.0 million and $0.9 million, respectively, for the quarters ended June 30, 2026 and 2025.

Six

Months Ended June 30, 2026 Financial Results

Lipocine reported a net loss of $6.3 million, or ($0.84) per diluted share, for the six months ended June 30, 2026, compared to a net loss of

$4.1 million, or ($0.76) per diluted share, for the six months ended June 30, 2025.

Lipocine recognized revenue of $309,000 and $717,000 during the six months ended June 30, 2026 and 2025, respectively. Revenue during the six months ended June 30, 2026 consisted entirely of royalty revenue from TLANDO sales. There was $500,000 of license revenue and $217,000 in royalty revenue during the same period in 2025.

Research and development expenses were $4.8 million and $3.2 million, respectively, for the six-month periods ended June 30, 2026 and 2025. The increase was driven primarily by costs related to the LPCN 1154 Phase 3 study and an increase in personnel expense, partially offset by a decrease in various research and development costs.

General and administrative expenses were $2.2 million and $2.0 million, respectively, for the six-month periods ended June 30, 2026 and 2025.

The increase was primarily a result of an increase in consulting and professional fees and an increase in various general and administrative fees.

Interest and investment income was $0.4 million for each of the six-month periods ended June 30, 2026 and 2025.

For further detail on Lipocine’s financial results for the three and six months ended June 30, 2026, refer to the Company’s Form

10-Q filed with the SEC.

About

Lipocine

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery.

Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.

Lipocine’s development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder,

LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenues:License revenue$-500,000$-500,000
Revenues:Royalty revenue190,099122,849309,496216,713
Revenues:Total revenues190,099622,849309,496716,713
Operating expenses:Research and development2,041,3892,136,7694,805,7823,198,341
Operating expenses:General and administrative990,956890,4332,195,4252,012,910
Operating expenses:Total operating expenses3,032,3453,027,2027,001,2075,211,251
Operating expenses:Operating loss-2,842,246-2,404,353-6,691,711-4,494,538
Other income:Interest and investment income219,851198,637397,422424,149
Other income:Total other income219,851198,637397,422424,149
Other income:Loss before income tax expense-2,622,395-2,205,716-6,294,289-4,070,389
Other income:Income tax expense-200-200-200
Other income:Net loss attributable to common shareholders-2,622,595-2,205,716-6,294,489-4,070,589
Other income:Basic loss per share attributable to common stock-0.32-0.41-0.84-0.76
Other income:Weighted average common shares outstanding, basic8,216,9885,351,9577,509,9235,350,267
Other income:Diluted loss per share attributable to common stock-0.32-0.41-0.84-0.76
Other income:Weighted average common shares outstanding, diluted8,216,9885,351,9577,509,9235,350,267
Comprehensive loss:Net loss-2,622,595-2,205,716-6,294,489-4,070,589
Comprehensive loss:Net unrealized loss on marketable investment securities-6,207-6,764-17,846-10,381
Comprehensive loss:Comprehensive loss-2,628,802-2,212,480-6,312,335-4,080,970

Balance Sheet

December 31, — (Unaudited)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents4,979,4305,205,842
Current assets:Marketable investment securities18,287,1799,724,545
Current assets:Accrued interest income101,06514,189
Current assets:License fee and royalties receivable190,0991,145,390
Current assets:Prepaid and other current assets179,004787,600
Current assets:Total current assets23,736,77716,877,566
Current assets:Property and equipment, net of accumulated depreciation of $1,313,541 and $1,284,079 respectively74,831104,293
Current assets:Other assets23,75323,753
Current assets:Total assets23,835,36117,005,612
Current liabilities:Accounts payable680,525971,822
Current liabilities:Accrued expenses1,067,4321,236,374
Current liabilities:Deferred revenue320,000320,000
Current liabilities:Total current liabilities2,067,9572,528,196
Current liabilities:Total liabilities2,067,9572,528,196
Stockholders’ equity:Common stock, par value $0.0001 per share, 75,000,000 shares authorized; 8,244,589 and 6,158,779 issued and 8,244,253 and 6,158,443 outstanding, respectively9,1538,944
Stockholders’ equity:Additional paid-in capital237,503,220223,901,106
Stockholders’ equity:Treasury stock at cost, 336 shares-40,712-40,712
Stockholders’ equity:Accumulated other comprehensive income-13,4014,445
Stockholders’ equity:Accumulated deficit-215,690,856-209,396,367
Stockholders’ equity:Total stockholders’ equity21,767,40414,477,416
Stockholders’ equity:Total liabilities and stockholders’ equity23,835,36117,005,612
Full release

This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995 and include statements that are not historical facts regarding our development of our products and product candidates and related efforts with the FDA, including the timing of clinical trials and regulatory submissions, the potential uses and benefits of our products and product candidates, the commercial potential for our product candidates, and potential strategic partnerships and other opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory... (truncated)g the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on

Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

SOURCE

Lipocine Inc.

For further information:

Krista

Fogarty

Phone:

(801) 994-7383 kf@lipocine.com

Investors:

PJ

Kelleher

Phone:

(617) 430-7579 pkelleher@lifesciadvisors.com

LIPOCINE

INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited)

LIPOCINE

INC. AND SUBSIDIARIES

Condensed

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lipocine earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.